NCT06081166

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

A Study to Evaluate the Effect of Daily Doses of Obicetrapib Tablets on the Pharmacokinetics of Atorvastatin Calcium Tablets or Rosuvastatin Calcium Tablets in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: NewAmsterdam Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A study to evaluate impact of Obicetrapib on PK levels of Atorvastatin and Rosuvastatin

Detailed description

A Study to Evaluate the Effect of Daily Doses of Obicetrapib Tablets on the Pharmacokinetics of Atorvastatin Calcium Tablets or Rosuvastatin Calcium Tablets in Healthy Adult Subjects

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Obicetrapib	obicetrapib 10 mg daily
DRUG	Atorvastatin Calcium	Atorvastatin 80 mg
DRUG	Rosuvastatin Calcium	Rosuvastatin 40 mg

Timeline

• Start date: 2023-11-11
• Primary completion: 2023-12-02
• Completion: 2024-01-22
• First posted: 2023-10-13
• Last updated: 2025-05-22

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study